# A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus

> **NCT01702740** · PHASE1 · COMPLETED · sponsor: **Centocor Research & Development, Inc.** · enrollment: 49 (actual)

## Conditions studied

- Lupus Erythematosus, Cutaneous
- Lupus Erythematosus, Systemic

## Interventions

- **DRUG:** 1 mg/kg CNTO 136
- **DRUG:** 4 mg/kg CNTO 136
- **DRUG:** 10 mg/kg CNTO 136
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01702740
- **Lead sponsor:** Centocor Research & Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01702740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01702740, "A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01702740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*